Multi-biomarker analysis in patients after transcatheter aortic valve implantation (TAVI)

References

• Andreasen, P.A., et al., 1997. The urokinase-type plasminogen activator system in cancer metastasis: a review. International journal of cancer, 72 (1), 1–22. doi:10.1002/(SICI)1097-0215(19970703)72:1.
   PubMed Web of Science ®Google Scholar
• Baldenhofer, G., et al., 2014. Galectin-3 predicts short- and long-term outcome in patients undergoing transcatheter aortic valve implantation (TAVI). Int journal of cardiology, 177 (3), 912–917. doi:10.1016/j.ijcard.2014.10.010.
   PubMed Web of Science ®Google Scholar
• Basar, N., et al., 2011. Lower Fetuin-A Predicts Angiographic Impaired Reperfusion and Mortality in ST-Elevation Myocardial Infarction. Journal of investigative medicine, 59 (5), 816–822. doi:10.2310/JIM.0b013e318214b578.
   PubMed Web of Science ®Google Scholar
• Bashore, T., et al., 1991. Percutaneous balloon aortic valvuloplasty. Acute and 30-day follow-up results in 674 patients from the NHLBI Balloon Valvuloplasty Registry. Circulation, 84 (6), 2383–2397. http://www.ncbi.nlm.nih.gov/pubmed/1959194. Accessed January 7, 2017.
   PubMed Web of Science ®Google Scholar
• Baumgartner, H., et al., 2017. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European heart journal, 38 (36), 2739–2791. doi:10.1093/eurheartj/ehx391.
   PubMed Web of Science ®Google Scholar
• Ben-Dor, I., et al., 2010. Complications and outcome of balloon aortic valvuloplasty in high-risk or inoperable patients. JACC cardiovascular interventions, 3 (11), 1150–1156. doi:10.1016/j.jcin.2010.08.014.
   PubMed Web of Science ®Google Scholar
• Bhardwaj, A. and Januzzi, J.L., Jr 2010. ST2: a novel biomarker for heart failure. Expert review of molecular diagnostics, 10 (4), 459–464. doi:10.1586/erm.10.25.
   PubMed Web of Science ®Google Scholar
• Bootcov, M.R., et al., 1997. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily . Proceedings of the national academy of sciences of the United States of America, 94 (21), 11514–11519.
   PubMed Web of Science ®Google Scholar
• Boscheri, A., et al., 2010. Correlation of heart-type fatty acid-binding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk. American heart Journal, 160 (2), 294–300. doi:10.1016/j.ahj.2010.05.010.
   PubMed Web of Science ®Google Scholar
• Burke, A.P., Kolodgie, F.D., and Virmani, R., 2007. Fetuin-A, valve calcification, and diabetes: What do we understand?. Circulation, 115 (19), 2464–2467. doi:10.1161/CIRCULATIONAHA.107.698324.
   PubMed Web of Science ®Google Scholar
• Cotter, G., et al., 2015. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: Results from the RELAX-AHF study. European journal of heart failure, 17 (11), 1133–1143. doi:10.1002/ejhf.331.
   PubMed Web of Science ®Google Scholar
• Cribier, A., et al., 2002. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation, 106 (24), 3006–3008. http://www.ncbi.nlm.nih.gov/pubmed/12473543. Accessed December 18, 2016.
   PubMed Web of Science ®Google Scholar
• Drews, T., et al., 2011. Transcranial Doppler sound detection of cerebral microembolism during transapical aortic valve implantation. The thoracic and cardiovascular surgeon, 59 (04), 237–242. doi:10.1055/s-0030-1250495.
   PubMedGoogle Scholar
• Eapen, D.J., et al., 2014. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. Journal of the American heart association, 3 (5), e001118. doi:10.1161/JAHA.114.001118.
   PubMed Web of Science ®Google Scholar
• Eggers, K.M., et al., 2010. Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circulation: Genomic and precision medicine, 3 (1), 88–96. doi:10.1161/CIRCGENETICS.109.877456.
   Google Scholar
• Eugen-Olsen, J., et al., 2010. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. Journal of internal medicine, 268 (3), 296–308. doi:10.1111/j.1365-2796.2010.02252.x.
   PubMed Web of Science ®Google Scholar
• Felker, G.M., et al., 2012. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circulation: heart failure, 5 (1), 72–78. doi:10.1161/CIRCHEARTFAILURE.111.963637.
   PubMed Web of Science ®Google Scholar
• Figulla, H.R., et al., 2016. The transcatheter valve technology pipeline for treatment of adult valvular heart disease. European heart journal, 37 (28), 2226–2239. doi:10.1093/eurheartj/ehw153.
   PubMed Web of Science ®Google Scholar
• George, M., et al., 2015. Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study. Therapeutic advances in cardiovascular diseases, 9 (5), 275–284. doi:10.1177/1753944715578405.
   PubMedGoogle Scholar
• Gooley, R., Cameron, J.D., and Meredith, I.T., 2015. Transcatheter aortic valve implantation – yesterday, today and tomorrow. Heart lung and circulation, 24 (12), 1149–1161. doi:10.1016/j.hlc.2015.07.017.
   PubMed Web of Science ®Google Scholar
• Gröschel, K., et al., 2012. Growth-differentiation factor-15 and functional outcome after acute ischemic stroke. Journal of neurology, 259 (8), 1574–1579. doi:10.1007/s00415-011-6379-0.
   PubMed Web of Science ®Google Scholar
• Gucuk Ipek, E., et al., 2016. Evaluation of galectin-3 levels in acute coronary syndrome. Annales de cardiologie angeiologie, 65 (1), 26–30. doi:10.1016/j.ancard.2015.09.046.
   PubMedGoogle Scholar
• Gyetko, M.R., Aizenberg, D., and Mayo-Bond, L., 2004. Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro. Journal of leukocyte biology, 76 (3), 648–656. doi:10.1189/jlb.0104023.
   PubMed Web of Science ®Google Scholar
• Holmes, D.R., Nishimura, R.A., and Reeder, G.S., 1991. In-hospital mortality after balloon aortic valvuloplasty: frequency and associated factors. Journal of the American college of cardiology, 17 (1), 189–192. http://www.ncbi.nlm.nih.gov/pubmed/1987225. Accessed January 7, 2017.
   PubMed Web of Science ®Google Scholar
• Huai, Q., et al., 2006. Structure of human urokinase plasminogen activator in complex with its receptor. Science (80-). Science, 311 (5761), 656–659. doi:10.1126/science.1121143.
   PubMed Web of Science ®Google Scholar
• Jung, C., et al., 2017. Microparticles in patients undergoing transcatheter aortic valve implantation (TAVI). Heart and vessels, 32 (4), 458–466.,
   PubMed Web of Science ®Google Scholar
• Ky, B., et al., 2011. High-Sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circulation: heart failure, 4 (2), 180–187. doi:10.1161/CIRCHEARTFAILURE.110.958223.
   PubMed Web of Science ®Google Scholar
• Lala, R.I., et al., 2015. Galectin-3 in heart failure pathology – “another brick in the wall”?. Acta cardiologica, 70 (3), 323–331. doi:10.2143/AC.70.3.3080637.
   PubMed Web of Science ®Google Scholar
• Lauten, A., et al., 2011. Microvascular tissue perfusion is impaired in acutely decompensated heart failure and improves following standard treatment. Europen journal of heart failure, 13 (7), 711–717. doi:10.1093/eurjhf/hfr043.
   PubMed Web of Science ®Google Scholar
• Lauten, A., et al., 2014. Impact of ischemia-reperfusion on extracellular matrix processing and structure of the basement membrane of the heart. PLoS one, 9 (3), e92833. doi:10.1371/journal.pone.0092833.
   PubMed Web of Science ®Google Scholar
• Lichtenauer, M., et al., 2017. A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure. Europen journal of internal medicine, 44, 31–38. doi:10.1016/j.ejim.2017.05.027.
   PubMed Web of Science ®Google Scholar
• Lichtenauer, M., et al., 2018. Specifics of fetuin-A levels in distinct types of chronic heart failure. Journal of clinical laboratory analysis, 32 (1), e22179. doi:10.1002/jcla.22179.
   Web of Science ®Google Scholar
• Lichtenauer, M., et al., 2015. Simulated temporary hypoxia triggers the release of CD31+/Annexin + endothelial microparticles: A prospective pilot study in humans. Clinical hemorheology and microcirculation, 61 (1), 83–90. doi:10.3233/CH-141908.
   PubMed Web of Science ®Google Scholar
• Lim, P., et al., 2007. Fetuin-A is an independent predictor of death after st-elevation myocardial infarction. Clinical chemistry, 53 (10), 1835–1840. doi:10.1373/clinchem.2006.084947.
   PubMed Web of Science ®Google Scholar
• Lindahl, B., 2013. The story of growth differentiation factor 15: Another piece of the puzzle. Clinical chemistry, 59 (11), 1550–1552. doi:10.1373/clinchem.2013.212811.
   PubMed Web of Science ®Google Scholar
• Lindman, B.R., et al., 2016. Calcific aortic stenosis. Nature reviews disease primers, 2, 16006. doi:10.1038/nrdp.2016.6.
   PubMed Web of Science ®Google Scholar
• Maiolino, G., et al., 2015. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease significance. Arteriosclerosis, thrombosis, and vascular biology, 35 (3), 725–732. doi:10.1161/ATVBAHA.114.304964.
   PubMed Web of Science ®Google Scholar
• Mueller, T., and Dieplinger, B., 2016. Soluble ST2 and Galectin-3: what we know and don’t know analytically. EJIFCC, 27 (3), 224–237. http://www.ncbi.nlm.nih.gov/pubmed/27683536. Accessed April 8, 2017.
   PubMedGoogle Scholar
• Niizeki, T., et al., 2008. Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure. Circulation journal, 72 (1), 109–114.
   PubMed Web of Science ®Google Scholar
• Selle, A., et al., 2014. Impact of rapid ventricular pacing during TAVI on microvascular tissue perfusion. Clinical research in cardiology, 103 (11), 902–911. doi:10.1007/s00392-014-0728-9.
   PubMed Web of Science ®Google Scholar
• Selleri, C., et al., 2005. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood, 105 (5), 2198–2205. doi:10.1182/blood-2004-06-2424.
   PubMed Web of Science ®Google Scholar
• Sun, Z.-L., et al., 2014. Serum Fetuin-A levels in patients with cardiovascular disease: a meta-analysis. BioMed research international, 2014, 1–9. doi:10.1155/2014/691540.
   Google Scholar
• Svensson, L.G., et al., 2013. A comprehensive review of the PARTNER trial. Journal of thoracic and cardiovascular surgery, 145 (3), S11–S16. doi:10.1016/j.jtcvs.2012.11.051.
   PubMed Web of Science ®Google Scholar
• Uitterdijk, A., et al., 2013. Serial measurement of hFABP and high-sensitivity troponin I post-PCI in STEMI: how fast and accurate can myocardial infarct size and no-reflow be predicted?. American Journal of physiology: heart and circulatory physiology, 305 (7), H1104–H1110. doi:10.1152/ajpheart.00447.2013.
   PubMed Web of Science ®Google Scholar
• Van Der Velde, A.R., et al., 2013. Prognostic value of changes in galectin-3 levels over time in patients with heart failure data from CORONA and COACH. Circulation heart failure, 6 (2), 219–226. doi:10.1161/CIRCHEARTFAILURE.112.000129.
   PubMed Web of Science ®Google Scholar
• Vörös, K., et al., 2011. Serum fetuin-A in metabolic and inflammatory pathways in patients with myocardial infarction. European journal of clinical investigation, 41 (7), 703–709., doi:10.1111/j.1365-2362.2010.02456.x.
   PubMed Web of Science ®Google Scholar
• Wernly, B., et al., 2017. Soluble ST2 predicts 1-year outcome in patients undergoing transcatheter aortic valve implantation. European journal of clinical investigation, 47 (2), 149–157. doi:10.1111/eci.12719.
   PubMed Web of Science ®Google Scholar
• Wollert, K.C. and Kempf, T., 2012. Growth differentiation factor 15 in heart failure: an update. Current heart failure reports, 9 (4), 337–345. doi:10.1007/s11897-012-0113-9.
   PubMedGoogle Scholar
• Xu, X., Li, Z., and Gao, W., 2011. Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside. Biomarkers, 16 (6), 466–475. doi:10.3109/1354750X.2011.580006.
   PubMed Web of Science ®Google Scholar
• Zhao, Z.-W., et al., 2013. Serum fetuin-A levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes. Biomarkers, 18 (2), 160–164. doi:10.3109/1354750X.2012.762806.
   PubMed Web of Science ®Google Scholar